CyberKnife provides men with prostate cancer treatment that doesn’t result in the consequences of surgery, nine weeks of daily radiation therapy or the surgical implanting of radioactive seeds.
Until the mid-1980s men diagnosed with prostate cancer were most likely detected at advanced, and often incurable, stages. A few men were diagnosed earlier when the cancer was discovered during surgery to relieve problems associated with urinating, but as a young doctor I saw countless men in misery with advanced prostate cancer that caused disabling and crippling bone metastases, urination problems, bleeding and swollen lower body parts—all due to the out of control growth of prostate cancer. We treated them by removing their testicles, giving them female hormones and delivering course after course of radiation to try to relieve their suffering.
In the mid-1980s it was discovered that prostate cancer was frequently associated with elevated levels of prostatic specific antigen (PSA). A PSA blood test was developed and it was the beginning of a revolution. Over the following years, the PSA test provided earlier detection of prostate cancer, which allowed for potentially curable treatments. As a result, the number of men who died of prostate cancer over the years has decreased tremendously.
Why did the PSA guidelines change?
Despite such an incredible difference the PSA test has made in the lives of millions of men over the last 30 years, the United States Preventive Services Task Force (USPSTF) recommended against using it to screen men for prostate cancer in 2011. The task force comprised of 16 volunteer clinicians including family physicians, general internal medicine physicians, nurses, obstetrician-gynecologists, occupational medicine physicians and pediatricians. There were no urologists or radiation oncologists directly involved in the recommendation.
The task force stated that they evaluated evidence on whether primary-care practitioners should recommend PSA screening. One of their concerns was the chance of a false-positive reading and the potential stress it could cause for patients. While this is a valid consideration, many physicians believe it is best for patients with elevated PSA levels to be under the care of a urologist to monitor their PSA levels and determine if they have prostate cancer.
I remember reading about the final recommendation of the USPSTF and predicted there would be unfortunate consequences for men, and this has proven true. The 2015 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium reported that since 2011, there has been an increase in the proportion of men diagnosed with higher-risk prostate cancers. With 233,000 new cases of prostate cancer every year, this means 14,000 more of them will be diagnosed with prostate cancer that is less likely to be cured.
The American Urologic Association, ASCO and the National Comprehensive Cancer Network—all specialists in treating prostate cancer—disagree with the USPSTF PSA screening recommendation.
European and American randomized studies have also shown a survival advantage for men who undergo screening compared with those who do not because prostate cancer is very curable when it is diagnosed early and classified as low risk. It is less curable when it is classified as intermediate and high risk.
I do not know how a stronger case can be made for PSA screening for prostate cancer.
I’ve been diagnosed with prostate cancer, now what?
After a prostate cancer diagnosis, there has been a trend for some patients to watch, wait and not treat until the prostate cancer gets worse. One reason for this approach is that the side effects of treatments like radical prostatectomy surgery, nine weeks of daily radiation therapy or surgical seed implants may have more negative consequences than actively watching the cancer.
Patients have an alternative – stereotactic body radiation therapy (SBRT) using the CyberKnife system. CyberKnife is a specialized radiation device attached to a robotic arm that allows us to “paint” the tumor with radiation and with extreme accuracy. This allows us to place the radiation on the prostate gland where it is needed and avoid the surrounding critical tissues (the rectum, bladder and nerves that control the ability to have erections). CyberKnife delivers an effective treatment in just five visits rather than 30-45 treatments using common radiation equipment. Less time in the clinic means less interruption of your life.
Over the past six years, I’ve treated hundreds of prostate patients with CyberKnife, and they would likely tell you the biopsy caused more side effects than the treatment did. For those with early low-risk tumors, there has not been a single failure to control their cancer. These results, along with those from 44 other CyberKnife centers throughout the United States, are published in the January 2015 paper titled “Multi-Institutional Registry for Prostate Cancer Radiosurgery,” a prospective observational clinical trial written by me, as well as Drs. Freemen and Perman, that presents data on 1,750 men treated with the CyberKnife for prostate cancer.
Anova is recognized as an international leader in the treatment of prostate cancer and I am seeing patients with prostate cancer from other cities, states and countries who take advantage of my expertise. If you or someone you care about has prostate cancer, you deserve the same opportunity. I encourage any man who is diagnosed with prostate cancer to contact Anova to learn more about treatment options. Our professional and friendly clinical team will provide you with exceptional care.
Treatment of your prostate cancer with CyberKnife SBRT can make it possible for you to be able to enjoy the rest of your life after prostate cancer.